Relationship Between Red Cell Distribution Width and Long-term Mortality in Patients with Non-ST Elevation Acute Coronary Syndrome
Overview
Authors
Affiliations
Objective: Red cell distribution width (RDW) has been reported to be a predictor of cardiac events in coronary artery disease (CAD). Here, we hypothesized that RDW level on admission would be predictive of adverse outcomes in non-ST elevation acute coronary syndrome (NST-ACS).
Methods: In total, 202 patients with NST-ACS (159 males and 43 females) were retrospectively analyzed. The patients were divided into two groups based on the 50th percentile of admission RDW levels. A high RDW group (n=100) was defined as those patients having RDW levels of >14.0. The relationship between RDW and primary endpoint (cardiovascular death), secondary endpoints [(reinfarction, repeat target vessel revascularization-percutaneous/surgical)], and major adverse cardiac events (MACE) were assessed. The median follow-up time was 18 (13-24) months.
Results: The patients in the high RDW group were older (62.9 vs. 57.5, p = 0.001). Multivessel disease, low-density lipoprotein, creatinine, platelet, CK-MB, troponin I, and RDW were higher (p = 0.047, p = 0.003, p = 0.012, p = 0.012, p = 0.017, p < 0.001, respectively), and gender (male/female), ejection fraction, and hemoglobin levels were lower (p = 0.021, p = 0.04, p = 0.016, respectively) in the high RDW group. Cardiovascular death and MACE were higher in the high RDW group (16% vs. 4.9%, p = 0.01, 52% vs. 31.4%, p = 0.003, respectively). By multiple regression analysis in 202 patients, age ≥ 65 and RDW >14.0% on admission were found to be powerful independent predictors of cardiovascular mortality (OR: 4.5, 95% CI: 1.5-13.1, p = 0.005, OR: 3.0, 95% CI: 1.0-8.9, p = 0.039, respectively).
Conclusion: A high RDW level on admission is associated with increased long-term mortality in patients with NST-ACS.
Nguyen Ngoc Dang H, Viet Luong T, Cao M, Bui V, Thien Tran T, Minh Nguyen H PLoS One. 2024; 19(7):e0301319.
PMID: 39042640 PMC: 11265657. DOI: 10.1371/journal.pone.0301319.
Gupta M, Yadav G, Singh Y, Bhalekar A J Anaesthesiol Clin Pharmacol. 2021; 36(4):531-534.
PMID: 33840936 PMC: 8022044. DOI: 10.4103/joacp.JOACP_105_19.
Latif A, Ahsan M, Lateef N, Kapoor V, Fazeel H, Razzaq F Curr Cardiol Rev. 2021; 17(6):e051121191160.
PMID: 33563170 PMC: 8950499. DOI: 10.2174/1573403X17666210204154812.
Abrahan 4th L, Ramos J, Cunanan E, Tiongson M, Punzalan F Cardiol Res. 2018; 9(3):144-152.
PMID: 29904449 PMC: 5997444. DOI: 10.14740/cr732w.
Chang X, Zhang S, Wang H, Zhang M, Zheng W, Ma H Oncotarget. 2018; 9(17):13971-13980.
PMID: 29568409 PMC: 5862630. DOI: 10.18632/oncotarget.24128.